Mock James M 4

What Happened James M. Mock, Chief Financial Officer of Moderna (MRNA), exercised/converted derivatives on February 27, 2026 (totaling 11,004 shares: 329 + 774 + 9,901). To satisfy tax withholding obligations, 5,323 of those shares (160 + 375 + 4,788) were withheld/paid at $51.71 per share, resulting in $275,252 in tax-withholding proceeds paid. On March 1, 2026, Mock was recorded as acquiring two RSU awards/awards totaling 87,208 shares (37,639 and 49,569), reported as derivative awards.

Key Details

• Transaction dates: exercise/conversion and withholding on 2026-02-27; grants/awards recorded 2026-03-01. Form filed 2026-03-03 (within required reporting window).
• Withheld/disposed shares for tax: 160 @ $51.71 ($8,274); 375 @ $51.71 ($19,391); 4,788 @ $51.71 ($247,587). Total tax withholding = $275,252.
• Derivative conversions/exercises: 329, 774 and 9,901 shares reported as exercised/converted (some line items shown at $0.00 as a derivative conversion/formality).
• Awards received: 37,639 and 49,569 RSU-type awards reported as acquired (derivative); vesting is subject to the company’s schedule (see footnotes).
• Footnotes of note: F2 = shares withheld at the Reporting Person’s election to satisfy tax withholding; F3–F5/F7 describe 25% initial vest and subsequent quarterly vesting schedules; F6 notes future option vesting beginning March 1, 2027.
• Shares owned after the transaction: not specified in the supplied summary of the filing.

Context

• This appears to be a net share settlement/tax-withholding associated with exercises/conversions and RSU activity (not an open-market sale by the insider). Net-settlements to cover taxes are routine and do not necessarily indicate a view on the company’s prospects.
• The filing was submitted on March 3, 2026 for transactions on Feb 27 and Mar 1, which is within the typical Form 4 reporting window (timely).